SKIN vs. LUNG, NVRO, TCMD, GUTS, CERS, ANIK, TMCI, ME, OSUR, and TLSI
Should you be buying Beauty Health stock or one of its competitors? The main competitors of Beauty Health include Pulmonx (LUNG), Nevro (NVRO), Tactile Systems Technology (TCMD), Fractyl Health (GUTS), Cerus (CERS), Anika Therapeutics (ANIK), Treace Medical Concepts (TMCI), 23andMe (ME), OraSure Technologies (OSUR), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical" sector.
Beauty Health (NASDAQ:SKIN) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.
Beauty Health has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Pulmonx has lower revenue, but higher earnings than Beauty Health. Pulmonx is trading at a lower price-to-earnings ratio than Beauty Health, indicating that it is currently the more affordable of the two stocks.
Beauty Health received 10 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 48.78% of users gave Beauty Health an outperform vote while only 43.48% of users gave Pulmonx an outperform vote.
In the previous week, Beauty Health had 26 more articles in the media than Pulmonx. MarketBeat recorded 26 mentions for Beauty Health and 0 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.47 beat Beauty Health's score of 0.85 indicating that Pulmonx is being referred to more favorably in the news media.
Beauty Health has a net margin of -20.48% compared to Pulmonx's net margin of -80.46%. Beauty Health's return on equity of -0.02% beat Pulmonx's return on equity.
93.3% of Beauty Health shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 41.0% of Beauty Health shares are owned by company insiders. Comparatively, 5.7% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Beauty Health presently has a consensus price target of $6.29, suggesting a potential upside of 143.63%. Pulmonx has a consensus price target of $16.33, suggesting a potential upside of 83.52%. Given Beauty Health's higher possible upside, equities analysts clearly believe Beauty Health is more favorable than Pulmonx.
Summary
Beauty Health beats Pulmonx on 13 of the 18 factors compared between the two stocks.
Get Beauty Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKIN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SKIN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beauty Health Competitors List
Related Companies and Tools
